Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25278170 | 0.91 | AAK1 (0.48) | AAK1PRMT5WDR77HIF1AATR | |
| SCHEMBL23792864 | 0.89 | AAK1 (0.46) | AAK1PRMT5WDR77HIF1ADGAT1 | |
| SCHEMBL21509658 | 0.87 | AAK1 (0.47) | AAK1PRMT5WDR77HIF1ADGAT1 | |
| SCHEMBL1646602 | 0.87 | AAK1 (0.52) | AAK1PRMT5WDR77HIF1ADGAT1 | |
| SCHEMBL20502655 | 0.86 | AAK1 (0.46) | AAK1PRMT5WDR77HIF1ADGAT1 | |
| SCHEMBL21510059 | 0.86 | AAK1 (0.46) | AAK1PRMT5WDR77HIF1ADGAT1 | |
| SCHEMBL31113485 | 0.85 | PRMT5 (0.48) | AAK1PRMT5WDR77HIF1ADGAT1 | |
| SCHEMBL65967 | 0.85 | AAK1 (0.51) | AAK1PRMT5WDR77HIF1ADGAT1 | |
| SCHEMBL30931999 | 0.84 | AAK1 (0.50) | AAK1PRMT5WDR77HIF1ADGAT1 | |
| SCHEMBL65546 | 0.84 | AAK1 (0.53) | AAK1PRMT5WDR77HIF1ADGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022120-A1 | Inhibitors of MENIN-MLL Interaction | BALA THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | BALA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| EP-4444313-A1 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4444300-A2 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107696-A2 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107687-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20190010167-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. | 2019-01-10 | — | — | US | disclosed |
| EP-3394064-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017112768-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112768-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| US-7709645-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090143352-A1 | PYRROLO-PYRIDINE KINASE MODULATIORS | SGX PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, BMI1 | AAK1 2080/4885PRMT5 78/4885WDR77 56/4885 |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | MLLT1, MEN1, BMI1 | AAK1 2080/4885PRMT5 78/4885WDR77 56/4885 |
| US-20260022120-A1 | Inhibitors of MENIN-MLL Interaction | MEN1, MLLT1, MLLT3 | AAK1 3652/4885PRMT5 304/4885WDR77 229/4885 |
| US-20190010167-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | AAK1 2103/4885PRMT5 128/4885WDR77 45/4885 |
| US-20090143352-A1 | PYRROLO-PYRIDINE KINASE MODULATIORS | MAP4K2, PDXK, MAP4K1 | AAK1 182/4885PRMT5 690/4885WDR77 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.